Drug intelligence / Profile preview

TL118

Development stage: Phase 2
Lead developer: Teligene
Modality: Small Molecules
Administration: Oral

Overview

TL118 is an orally administered small molecule that functions as a tropomyosin receptor kinase (TRK) inhibitor. It targets the TRK family, specifically TRKA, TRKB, and TRKC, which are encoded by the NTRK1, NTRK2, and NTRK3 genes, respectively. Oncogenic fusions involving these NTRK genes are known to drive the proliferation and spread of cancer cells. Developed by Teligene US, TL118 is being investigated for the treatment of solid tumors that harbor these specific NTRK gene fusions.

Targets

NTRK1 (Tropomyosin-related receptor kinase A)NTRK3 (Tropomyosin receptor kinase C)NTRK2 (Tropomyosin-related kinase receptor type B)

Beyond the preview

Go deeper on TL118.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on TL118.

Explore the full profile